NCT05393271View on ClinicalTrials.gov

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

April 24, 2023

Study Completion Date

April 24, 2023

Conditions
HIV Infections
Interventions
DRUG

VH4011499

VH4011499 will be administered.

DRUG

Placebo

Placebo will be administered.

DRUG

Midazolam

Midazolam will be administered

Trial Locations (2)

78744

GSK Investigational Site, Austin

89113

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY